2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6213 Glucagon-like peptide-1 receptor agonist and risk of venous and arterial thrombosis in autoimmune hemolytic anemia: A propensity-matched retrospective cohort study

Vanessa Velazquez, MD, Jacob Schmelz, MD2, Colton Jones, MD, Hematology, Oncologyfellow3, Usha S Perepu, MD4
1 UT Health San Antonio, San Antonio, Texas, United States
2 UT Health San Antonio, San Antonio, Texas, United States
3 UT Health San Antonio, San Antonio, Texas, United States
4 UT Health San Antonio, San Antonio, Texas, United States
Background
Autoimmune hemolytic anemia (AIHA) carries a substantial thrombotic burden, with event rates of approximately 11-25% across referral cohorts, including both venous thromboembolism (VTE) and arterial events. The risk is driven by complement activation, free heme, neutrophil extracellular traps, and platelet and endothelial activation. No validated risk score performs adequately in AIHA, and there is no consensus indication for primary thromboprophylaxis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) and obesity and exert weight-loss–independent antiplatelet, anti-inflammatory, and endothelium-stabilizing effects relevant to hemolysis-associated hypercoagulability. Whether GLP-1 RA exposure modifies thrombotic risk in AIHA is unknown.
Methods
We performed a retrospective new-user cohort study using the TriNetX global federated network. Eligible adults had AIHA (warm, cold, mixed, or drug-induced) plus T2DM or obesity. Exposed patients were initiated on a GLP-1 RA ≥30 days after AIHA diagnosis, with the index date defined as the first prescription; unexposed patients had no GLP-1 RA exposure and were assigned an equivalent index date to limit immortal-time bias. Patients with inherited hemolytic anemias and non-immune hemolytic anemias such as paroxysmal nocturnal hemoglobinuria, hemolytic uremic syndrome, and thrombotic microangiopathy were excluded. Cohorts were 1:1 propensity score–matched on age, sex, race/ethnicity, baseline hemoglobin, AIHA-directed therapy (corticosteroids, rituximab, immunoglobulin), malignancy, and pregnancy. Co-primary outcomes were VTE, myocardial infarction (MI), and cerebrovascular accident (CVA), analyzed by Cox proportional hazards models with hazard ratios (HR) and 95% CI.
Results
After matching, 1,234 patients were included per cohort. Median age was 58 years (GLP-1 RA) versus 60 years (control); 67% versus 69% were female and 69% of both cohorts were White. The median follow-up was 650 days. AIHA-directed therapy was balanced and corticosteroid-predominant (prednisone 62% vs 61%; dexamethasone 53% vs 52%; rituximab 14% vs 14%; immunoglobulin 11% vs 11%). Residual imbalance persisted in markers of hemolytic activity and glycemia: mean hemoglobin was 12.8 versus 10.0 g/dL and mean HbA1c was 6.7% versus 6.0%. GLP-1 RA exposure was associated with lower incidence of VTE (1.7% vs 4.8%; HR 0.35, 95% CI 0.21–0.61; p<0.001), MI (1.3% vs 4.7%; HR 0.27, 95% CI 0.15–0.48; p<0.001), and CVA (1.2% vs 3.5%; HR 0.35, 95% CI 0.19–0.65; p<0.001).
Conclusions
In this propensity-matched analysis of patients with AIHA and coexisting T2DM or obesity, GLP-1 RA exposure was associated with lower risks of VTE, MI, and CVA. The magnitude of these associations exceeds the effect sizes reported in GLP-1 RA cardiovascular outcome trials, and the persistent hemoglobin difference suggests that lower AIHA disease activity among treated patients contributes to the observed benefit; these findings are therefore hypothesis-generating rather than causal. Given the high thrombotic burden and absence of validated risk stratification in AIHA, prospective evaluation with adjustment for LDH, transfusion burden, and hemolytic relapse frequency is warranted.
Vanessa Velazquez, MD: No relevant conflicts of interest to declare.